Oncology Best Practice™: Informed Decision Making in Advanced NSCLC
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hours.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Lilly.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
|Interested in hosting an Oncology Best Practice™ NSCLC program? Contact Sara Shaughnessy at Sshaughnessy@gotoper.com or call (609) 378-3701. Click here to download the Educational Request Form.|
Oncology Best Practice™ is a series of interactive meetings hosted by leading cancer centers, large oncology practice groups, and community hospitals throughout the United States. These 1-hour meetings will be led by a nationally renowned expert in non-small-cell lung cancer (NSCLC). The program will address unmet needs that persist for patients with lung cancer, followed by current and emerging therapies to address these medical needs. Ample discussion time will allow participants to interact with expert faculty to address challenges in their practice.
Why Should I Attend?
- Interact with a nationally recognized expert in lung cancer and local peers at each meeting.
- Explore the application of clinical data and expert guidelines to common, challenging patient scenarios.
Develop strategies for challenging subsets of patients with NSCLC:
- How to choose the best first-line therapy for patients with advanced, squamous NSCLC.
- Optimizing subsequent lines of therapy for patients with nonsquamous NSCLC.
- Assessing true clinical benefit of targeted agents, including cytostatic effects.
- Discuss the potential clinical implications of recent data on antibodies to inhibit growth factor receptors and immune checkpoints in patients with squamous or nonsquamous NSCLC.
- Learn about ongoing clinical trial opportunities for your patients.
This activity is intended to meet the educational needs of oncologists and nurses who care for patients with lung cancer. Fellows, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer may also participate.
Upon completion of this activity, participants will be able to:
- Discuss recent clinical trial evidence that can be applied to front-line clinical decision making in advanced NSCLC.
- Assess methods to facilitate tumor tissue testing to identify tumor characteristics that allow for personalized care strategies for patients with lung cancer.
- Explain how to monitor response in patients receiving treatment for advanced NSCLC, as well as key information that informs decisions on switching therapies.
- Summarize strategies to proactively plan for and manage treatment-related, adverse events in patients with advanced NSCLC.
David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Calendar of Events